Trump Announcement: IVF Access May Expand in 2026. Here’s What You Should Know
On October 16, 2025, President Trump announced a set of proposals aimed at making fertility care more affordable and accessible. While the announcement has sparked excitement across the fertility community, it’s important to understand what’s changing - and what’s not - just yet.
What Was Announced?
The administration introduced several initiatives, including:
-
Discounted IVF Medications: A partnership with EMD Serono to offer reduced pricing on select medications like Gonal-f, Ovidrel, and Cetrotide through a new platform called TrumpRx.
-
Encouraging Employer Benefits: Guidance for employers to offer fertility benefits as standalone options, similar to dental or vision plans.
-
FDA Fast-Tracking: The fertility drug Pergoveris will be reviewed on an expedited timeline to potentially speed up its availability in the U.S.
What This Means for You—Right Now
While these announcements are promising, the proposed programs are not yet active. Here’s what to keep in mind:
-
The medication discounts are expected to begin in 2026, but no official start date has been confirmed.
-
The discounts apply only to specific medications, which may not be used in every fertility treatment plan.
-
There is no federal mandate requiring employers to offer fertility benefits - this remains optional.
Our Commitment to You
At Main Line Fertility, we’re closely monitoring these developments and will continue to provide updates as more information becomes available. Our team is here to help you navigate your options and make informed decisions about your care.
For full details, visit The Prelude Network.
Time is one of the most important factors in fertility care. If you’re trying to grow your family, don’t wait for future programs to begin. Many patients are able to conceive without IVF, and for those who need advanced treatment, we offer flexible financing options to make care more accessible.